Amgen's MariTide Obesity Drug Candidate Faces Scrutiny Over Bone Mineral Density Concerns
Key Insights
Amgen's obesity (search) drug candidate, MariTide, experienced a stock dip after data revealed potential bone mineral density loss in trial participants.
An analyst discovered previously unreported data in hidden tabs of a file associated with MariTide's early trial results.
The data indicated that participants, especially those on higher doses, experienced a reduction in bone mineral density.
Amgen's MariTide, an obesity (search) drug candidate, has come under increased scrutiny following the emergence of previously unreported data suggesting potential bone mineral density loss among trial participants. The revelation led to a significant market reaction, with Amgen's stock value decreasing by $12 billion.
The concerns were triggered by an analyst at Cantor Fitzgerald who discovered hidden data within a file attached to the publication of MariTide's early trial results. These hidden tabs contained data indicating that study participants experienced a reduction in bone mineral density, particularly those receiving higher doses of the drug. The analyst's note, widely shared among investors, highlighted these potential side effects, causing a 7% drop in Amgen's share price.
The unearthed data adds a layer of complexity to the development of MariTide, as bone mineral density is a critical factor in overall health. Further investigation will be needed to fully understand the extent and implications of this side effect. The market's reaction underscores the sensitivity surrounding potential safety issues in obesity (search) drugs, especially given the widespread interest and investment in this therapeutic area.